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ABSTRACT
We have previously identified flavin-containing monooxygenase
5 (FMO5) as a regulator of metabolic aging. The aim of the present
studywas to investigate the role of FMO5 in glucose homeostasis and
the impact of diet and gut flora on the phenotype ofmice in which the
Fmo5 gene has been disrupted (Fmo52/2mice). In comparison with
wild-type (WT) counterparts, Fmo52/2mice are resistant to age-
related changes in glucose homeostasis and maintain the higher
glucose tolerance and insulin sensitivity characteristic of young
animals. When fed a high-fat diet, they are protected against weight
gain and reduction of insulin sensitivity. The phenotype of Fmo52/2
mice is independent of diet and the gut microbiome and is deter-
mined solely by the host genotype. Fmo52/2 mice have metabolic
characteristics similar to those of germ-free mice, indicating that
FMO5 plays a role in sensing or responding to gut bacteria. In WT
mice, FMO5 is present in the mucosal epithelium of the gastrointes-
tinal tract where it is induced in response to a high-fat diet. In
comparison with WT mice, Fmo52/2 mice have fewer colonic goblet
cells, and they differ in the production of the colonic hormone resistin-
like molecule b. Fmo52/2 mice have lower concentrations of tumor
necrosis factor a in plasma and of complement component 3 in
epididymal white adipose tissue, indicative of improved inflammatory
tone. Our results implicate FMO5 as a regulator of bodyweight and of
glucose disposal and insulin sensitivity and, thus, identify FMO5 as a
potential novel therapeutic target for obesity and insulin resistance.
Introduction
Flavin-containing monooxygenases (FMOs) (Enzyme Commission
#1.14.13.8) of mammals play an important role in the NADPH-
dependent oxidative metabolism of a wide array of foreign chemicals
(Krueger and Williams, 2005). FMOs 1, 2, and 3 catalyze the N- and
S-oxygenation of a structurally diverse range of xenobiotic agents,
including therapeutic drugs, dietary components, and environmental
pollutants (Krueger and Williams, 2005; Phillips et al., 2007). FMO5
differs markedly from FMOs 1, 2, and 3 with respect to its substrate
specificities (Phillips and Shephard, 2017). Although FMO5 catalyzes
the N-oxygenation of short-chain aliphatic primary amines such as
N-octylamine (Overby et al., 1995) and the S-oxygenation of S-methyl-
esonarimod, an active metabolite of the antirheumatic agent esonarimod
(Ohmi et al., 2003; Zhang et al., 2007), it is apparently more efficient in
catalyzing the oxygenation of a variety of carbonyl compounds, via a Baeyer-
Villiger process (Fiorentini et al., 2016), including the anticancer drug E7016
(Lai et al., 2011) and the antibacterial agentMRX-I (Meng et al., 2015). FMOs
1, 2, and 3 (Siddens et al., 2014) and FMO5 (Fiorentini et al., 2016) can act
also as NADPH oxidases, producing hydrogen peroxide.
In human and mouse, the tissue-specific pattern of expression of FMO5
is similar, unlike those of FMO1 or FMO3, which show distinct differences
in hepatic expression between these species (Dolphin et al., 1991, 1996;
Janmohamed et al., 2004). FMO5 is most highly expressed in liver (Overby
et al., 1997; Zhang and Cashman, 2006) and skin (Janmohamed et al., 2001)
and is moderately expressed in other tissues, including the small intestine
(Hernandez et al., 2004; Zhang and Cashman, 2006; Fu et al., 2016).
Very few single-nucleotide polymorphisms (SNPs) have been identi-
fied in the coding region of the human FMO5 gene, and none has been
shown to influence enzyme activity (Furnes et al., 2003; Phillips et al.,
2007). FMO5 gene expression, however, is increased by several
chemicals, including the hormones progesterone (Miller et al., 1997) and
testosterone (Houseman et al., 2015) and the pregnane X receptor
ligands hyperforin (Krusekopf and Roots, 2005) and rifampicin
(Rae et al., 2001; Houseman et al., 2015). Activation of pregnane X
receptor has been proposed as a factor contributing to type 2 diabetes
(Hukkanen et al., 2014). Interindividual variation in the expression of
FMO5 in human liver has been reported (Overby et al., 1997). Given the
inducible nature of the gene, such variation is likely due to physiologic
or environmental factors.
Through the use of knockout mouse lines, we have shown that, in
addition to their involvement in the metabolism of foreign chemicals,
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two members of the FMO family, FMO1 and FMO5, play roles in
endogenous metabolism. FMO1 has been identified as a regulator of
energy homeostasis (Veeravalli et al., 2014), and FMO5 has been
identified as a promoter of metabolic aging (Gonzalez Malagon et al.,
2015). Homozygous knockout (Fmo52/2) mice exhibit an age-related
lean phenotype: in comparison with their wild-type (WT) counterparts, as
they age they gain less weight, store less fat in white adipose tissue
(WAT), have lower plasma concentrations of glucose and cholesterol,
and enhancedwhole-body energy expenditure, with no increase in physical
activity (Gonzalez Malagon et al., 2015).
The present study extends our characterization of the metabolic
phenotype of Fmo52/2mice, focusing on the potential role of FMO5 in
regulating glucose homeostasis and the effects on the phenotype of diet
and gut flora. We show that Fmo52/2 mice are resistant to age-related
changes in glucose homeostasis and are protected against weight gain
and reduction of insulin sensitivity in response to a high-fat diet. The
phenotype is independent of the gut microbiome, and our results
implicate FMO5 as an intestinal microbial sensor.
Materials and Methods
Animal Maintenance. Fmo52/2mice used in this study were generated on the
C57BL/6J background and back-crossed for eight generations, as described
previously (Gonzalez Malagon et al., 2015). WT C57BL/6J mice were used as
controls. Both mouse lines were bred and housed in the same room at University
College London (UCL). All experiments were performed on male animals. Mice
were given free access towater and fed ad libitumwith a standard chowdiet (Teklad
Global 18%Protein RodentDiet; Harlan Laboratories, Inc.,Madison,WI) or, where
specified, a high-fat diet (AIN-93M w/ 35% kcal fat; TestDiet, St. Louis, MO).
Tissue and blood samples were collected between 9:30 AM and 12:00 PM (noon),
unless stated otherwise. Animal procedures were carried out in accordance with the
UK Animal Scientific Procedures Act and with local ethics committee approval
(AnimalWelfare and Ethical ReviewBody) and appropriate HomeOffice Licenses.
Plasma Analyses. Blood was collected and plasma was isolated as described
previously (Hough et al., 2002). Mice fed a high-fat diet and their standard chow–
fed age-matched controls were starved overnight before blood withdrawal. The
concentration of glucose in plasma was determined via an autoanalyzer at the
Medical Research Council Harwell (Harwell, Oxfordshire, UK) Mammalian
Genomics Unit and in whole blood through the use of a CONTOUR XT Meter
(Bayer AG, Leverkusen, Germany). Commercially available enzyme-linked
immunosorbent assay kits were used to determine plasma concentrations of
insulin (Rat/Mouse Insulin ELISA; Millipore, Watford, Hertfordshire, UK) and
TNFa (TNFa Mouse EIA Kit; Enzo, Exeter, Devon, UK). Plasma lipopolysac-
charide was measured by Lonza Endotoxin Service Europe (Verviers, Belgium)
using the Limulus Amebocyte Lysate Assay.
Intraperitoneal Glucose Tolerance and Insulin Sensitivity Tests. Glucose
tolerance tests (GTTs) and insulin sensitivity tests (ISTs) were performed as
described previously (Heikkinen et al., 2007) in animals that had been fasted
either overnight (15 hours) (GTT) or for 6 hours (IST). Fasting blood glucose
concentrations were measured through the use of a CONTOURXTMeter (Bayer
AG). Animals were then injected intraperitoneally with glucose (2 g/kg b.wt.)
(GTT) or insulin (0.25 IU/kg b.wt.) (IST). Blood glucose concentration was then
measured 15, 30, 60, 90, and 120 minutes (GTT) or 15, 30, 45, 60, 75, and
90 minutes (IST) postinjection. For statistical analysis, area under the curve
(AUC) or inverse AUC was calculated as appropriate (Heikkinen et al., 2007).
Intestinal Microbiota Analysis. DNA was isolated from frozen fecal pellets
through the use of the Isolate Fecal DNAKit (Bioline, London, UK) according to
the manufacturer recommendations, except for an additional 30 minutes of
shaking after addition of lysis buffer. Bacterial 16S ribosomal RNA (rRNA) gene
sequences were amplified using the universal 16S rRNA primer pair, forward 8FE
(59-AGAGTTTGATCCTGGCTCAG-39) (Salzman et al., 2002) and reverse
1387r (59-GGGCGGTGTGTACAAGGC-39) (Marchesi et al., 1998), and Biotaq
DNA polymerase (Bioline). Approximately 16 ng of fecal DNA and 5 pmol each
of forward and reverse primers were used per 25-ml reaction volume. Polymerase
chain reaction conditions were 5 minutes at 95C, followed by 30 cycles of 95C
for 1 minute, 51C for 1 minute, and 72C for 1 minute, and a final elongation at
72C for 5 minutes. Amplification products were ligated into pGEM-T (Promega,
Southampton, Hampshire, UK). Electrocompetent Escherichia coli JM109 cells
were transformedwith ligation products. Recombinant colonies were individually
stabbed into agar-containing 96-well plates. Plasmid isolation and DNA
sequencing were performed by LGC Genomics GmbH (Berlin, Germany).
Sequences were identified by comparison with known 16S rRNA gene sequences
in the Ribosomal Database Project (http://rdp.cme.msu.edu).
Antibiotic Treatment. At 30 weeks of age, animals were given ampicillin
(1 g/l) and neomycin (0.5 g/l) in their drinking water for 14 days. Antibiotic-
containing water was replenished twice weekly, and animals were given free
access to the standard chow diet.
Histology and Immunohistochemistry. Sections of digestive tract were fixed
in 10% (v/v) neutral buffered formalin (Leica Biosystems, Milton Keynes,
Buckinghamshire, UK). Tissue samples were embedded in paraffin and sections
stained with hematoxylin and eosin at the Medical Research Council Mary Lyon
Centre (Harwell, Oxfordshire, UK). Immunohistochemistry of tissue sections was
performed by UCLAdvanced Diagnostics (London, UK). FMO5was detected using
a polyclonal antibody (16864-1-AP; ProteinTech, Manchester, UK), diluted 1:100
(AntibodyDiluentBackgroundReducing;Dako, Ely,Cambridgeshire,UK). RELMb
was detected using a polyclonal antibody (ab11429; Abcam, Cambridge, Cambridge-
shire, UK), diluted 1:400 (Bond Primary Antibody Diluent; Leica Biosystems). Cell
nuclei were counterstained with hematoxylin. Colonic sections were stained with
Alcian Blue and counterstained with Neutral Red (UCL Advanced Diagnostics).
Goblet cells were quantified as described previously (Mello et al., 2012).
Western Blot Analysis. Fecal samples, colon contents, and liver and epidid-
ymal adipose tissues were homogenized using a Tissue Lyser II (Qiagen, Crawley,
West Sussex, UK) in ice-cold Triton lysis buffer (1%Triton X-100, 140 mMNaCl,
10 mM Tris-HCl, pH 8, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride)
containing Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific,
Loughborough, Leicestershire, UK). To ensure sufficient homogenization samples
were agitated for an additional 15 minutes (liver and adipose tissue) or 40 minutes
(fecal and colon samples) at 4C. Homogenates were centrifuged at 12,000g for
20 minutes at 4C. For detection of FMO5 in fecal samples, homogenates were
concentrated by precipitation with trichloroacetic acid then resuspended in 200mM
Tris-HCl (pH 8.5), 10 mM EDTA, 6 M urea, 0.5% (w/v) SDS. Samples were
adjusted to final concentrations of 50 mM Tris-HCl, pH 6.8, 10% (v/v) glycerol,
2% (w/v) SDS, 0.25% (w/v) bromophenol blue, and 100 mM dithiothreitol.
Samples were then heated at 95C for 5 minutes and analyzed by SDS-PAGE and
western blotting. Proteins were detected by the use of antibodies against FMO5
(16864-1-AP; ProteinTech), b-actin (66009-1-Ig; Proteintech), RELMb (ab11429;
Abcam), complement component 3 (C3) (204869; Millipore), and enolase
(sc-15343; Santa Cruz Biotechnology, Heidelberg, Germany). For primary
antibodies against FMO5, RELMb, and enolase, a secondary anti-rabbit antibody
conjugated to horseradish peroxidase (HRP) [Donkey Anti-Rabbit IgG H+L
(HRP); Abcam] was used. For b-actin, goat anti-mouse secondary antibody IR
680 (Alexa Fluor A21057; Life Technologies Ltd, Paisley, UK) was used. For C3,
a secondary anti-goat antibody conjugated to HRP (Rabbit Anti-Goat IgG-HRP
Conjugate; Alpha Diagnostic, San Antonio, TX) was used. Blots were incubated
with secondary antibodies for 1 hour at room temperature before enhanced
chemiluminescence detection, as described previously (Gonzalez Malagon et al.,
2015), using an Odyssey Fc Dual-Mode Imaging System (LI-COR, Cambridge,
Cambridgeshire, UK). For fecal and colon contents, to control for protein loading,
the amount of protein loaded onto each well was assessed by scanning densitometry
of the whole length of each lane using GelQuant.Net software, version 1.8.2
(BiochemLabSolutions; biochemlabsolutions.com). Individual protein signals on
western blots were quantified using LI-COR Image Studio Lite, version 3.1.4.
Statistical Analysis. Data are expressed as the mean 6 S.E.M. Statistical
significance was determined using an unpaired two-tailed t test and GraphPad
Prism (version 6.0e; GraphPad Software, Inc., La Jolla, CA). The following
symbols were used throughout all figures and text to indicate the significance
value: *P , 0.05, **P , 0.01, ***P , 0.001, ****P , 0.0001.
Results
Fmo52/2Mice Are Resistant to Age-Related Changes in Glucose
Homeostasis and Insulin Sensitivity. The plasma concentration of
glucose in 6-week-old Fmo52/2 mice was similar to that in WT mice
(Fig. 1A). From 6 to 15 weeks of age it decreased, to the same extent, in
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both Fmo52/2 and WT mice. A similar decrease has been reported for
mice as they age from immature to young adult (Bailey and Flatt, 1982).
From 15 weeks of age, the plasma glucose concentration of WT mice,
but not of Fmo52/2 mice, increased and by 30 weeks was 10.85 6
0.20 mmol/l (n = 18) in WT mice and 9.21 6 0.35 mmol/l (n = 17) in
Fmo52/2mice (P, 0.001, Fmo52/2 versus WT) (Fig. 1A). The results
confirm and extend our previous findings on 10- and 30-week-old mice
(Gonzalez Malagon et al., 2015) and indicate that the lower plasma
concentration of glucose in Fmo52/2 mice compared with WT mice at
30 weeks of age is the result of a lack of increase, rather than a decrease,
in plasma glucose of Fmo52/2mice as they age from 15 to 30 weeks. At
15 and 30 weeks of age, both WT and Fmo52/2 mice responded to a
12-hour overnight withdrawal of food by decreasing their plasma
glucose concentrations by ;25% (data not shown).
At 10 weeks of age, the plasma concentration of insulin in Fmo52/2
and WT mice was the same (Fig. 1B). As mice aged, the plasma insulin
concentration ofWTmice increased but that of Fmo52/2mice remained
the same, and by 30 weeks of age the plasma insulin concentration of
WT mice (1.92 6 0.13 ng/ml; n = 3) was 3-fold more than that of
Fmo52/2 mice (0.63 6 0.08 ng/ml; n = 3; P , 0.01). Therefore, at
15 and 30 weeks of age, although the plasma concentration of glucose of
Fmo52/2 mice was the same or lower than that of WT mice (Fig. 1A),
Fmo52/2 mice required less insulin to maintain the concentration.
Glucose tolerances for Fmo52/2 and WT mice were the same at
15 weeks of age (Fig. 1C). By 30 weeks, Fmo52/2mice, despite having
lower plasma insulin concentrations than WT mice (Fig. 1B), had
significantly higher glucose tolerance (Fig. 1D). The similarity in peak
glucose concentration suggests no difference in pancreatic b-cell
function between Fmo52/2 and WT mice, whereas the larger AUC of
WTmice is indicative of greater whole-body insulin resistance. As early
as 10weeks of age,Fmo52/2mice responded to insulinmore quickly and
to a greater extent than didWTmice (Fig. 1E), indicating that the former
had greater basal insulin sensitivity. Our results demonstrate that
Fmo52/2 mice are resistant to the age-related changes in glucose
homeostasis and insulin sensitivity exhibited by their WT counterparts.
Fmo52/2 Mice Are Resistant to Weight Gain and Reduction of
Insulin Sensitivity in Response to a High-Fat Diet.When fed a high-
fat diet for a period of 6 weeks, 33-week-old WT mice increased in
weight from 37.66 0.7 to 46.26 0.9 g (n = 7), a gain of 23% (Fig. 2A).
In contrast,Fmo52/2mice gained noweight while being fed the high-fat
diet and by 39 weeks of age weighed 33.86 1.0 g (n = 6), 27% less than
WT mice (Fig. 2A). When fed a standard chow diet over the same
period, neither WT nor Fmo52/2 mice of this age increased weight
significantly (data not shown).When fed a standard chow diet, Fmo52/2
mice eat slightlymore thanWTmice (GonzalezMalagon et al., 2015). In
the case of the high-fat diet, owing to the consistency of the food pellets,
which caused them to crumble when eaten, it was not possible to
accurately measure food intake. However, the food hoppers of Fmo52/2
mice had to be replenished more frequently than those of WT mice,
suggesting that, as is the case when being fed the standard chow diet,
when fed a high-fat diet Fmo52/2 mice do not eat less than WT mice.
Our results demonstrate that, in contrast to WTmice, Fmo52/2mice are
resistant to high-fat diet–induced weight gain and that this is unlikely to
be a consequence of a reduced intake of food.
In response to a 12-hour overnight withdrawal of food, the plasma
concentration of glucose inFmo52/2mice fed a high-fat diet was reduced
to 6.986 0.78 mmol/l (n = 6), which was similar to the concentration in
fastedFmo52/2mice being fed a standard chowdiet (7.2860.20mmol/l;
n = 23). However, WT mice responded less well to a 12-hour fast when
being fed a high-fat diet than when being fed a standard chow diet,
reducing plasma glucose concentrations to 9.61 6 0.53 mmol/l (n = 7)
and 7.97 6 0.27 mmol/l (n = 20), respectively (P , 0.05).
Fig. 1. Fmo52/2 mice are resistant to age-related changes in
glucose homeostasis. (A) Plasma glucose concentration of
WT and Fmo52/2 [knockout (KO)] mice with age. 6 weeks:
n = 4 (WT), n = 5 (KO); 8 weeks: n = 9 (WT), n = 11 (KO);
10 weeks: n = 21 (WT), n = 24 (KO); 15 weeks: n = 18 (WT),
n = 23 (KO); 20 weeks: n = 10 (WT), n = 4 (KO); and 30 weeks:
n = 18 (WT), n = 17 (KO). (B) Plasma insulin concentration of WT
and Fmo52/2 (KO) mice with age: 10 and 15 weeks, n = 4;
30 weeks, n = 3. (C) GTT of 15-week-old WT and Fmo52/2 (KO)
mice (n = 6). Insert shows the AUC. (D) GTT of 30-week-old WT
and Fmo52/2 (KO) mice (n = 5). Insert shows the AUC. For GTT,
mice were starved for 15 hours before the test. (E) IST of
10-week-old WT and Fmo52/2 (KO) mice that had been starved
for 6 hours (n = 4). Insert shows inverse AUC (iAUC). Data are
expressed as the mean6 SEM. *P, 0.05, **P, 0.01, ***P, 0.001.
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The plasma concentration of insulin of WT mice fed a high-fat diet
was 10-fold higher than that of WT mice fed a standard chow diet (Fig.
2B). In contrast, in Fmo52/2 mice the high-fat diet had a much smaller
effect on plasma insulin, which was increased to a concentration similar
to that ofWTmice being fed a standard chow diet (Fig. 2B). The high-fat
diet significantly reduced the glucose tolerance of WT mice but had no
effect on that of Fmo52/2 mice (Fig. 2C). Our results demonstrate that,
in comparison with WT mice, Fmo52/2mice are resistant to changes in
glucose homeostasis as a consequence of being fed a high-fat diet. Our
finding that disruption of the Fmo5 gene renders mice resistant to weight
gain and a reduction of insulin sensitivity in response to a high-fat diet
suggests that FMO5 is involved in mediating such dietary-induced
physiologic effects.
FMO5 Is Induced in the Intestine in Response to a High-Fat
Diet. The amount of FMO5 present in fecal samples fromWTmice was
6-fold higher in animals fed a high-fat diet than in samples from WT
mice fed a standard chow diet (Fig. 2D), suggesting that intestinal
expression of the protein was increased in response to a high-fat diet.
However, this was not the case in liver (Fig. 2E), indicating that the high-
fat diet–induced expression of FMO5 was tissue specific.
The Phenotype of Fmo52/2 Mice Is Independent of the Gut
Microbiota. Five intestinal bacterial phyla were identified in WT and
Fmo52/2mice fed a standard chow diet: Actinobacteria, Proteobacteria,
Deferribacteres, Firmicutes, and Bacteroidetes, of which the Firmicutes
and Bacteroidetes were the most abundant (Fig. 3A). This is in
agreement with previous studies of WT mice (Ley et al., 2005). At
7 weeks of age, the Bacteroidetes dominated, and the gut microbial
community ratio of Bacteroidetes to Firmicutes was the same (4:1) in
WT and Fmo52/2 mice (Fig. 3A). As WT mice aged, the relative
abundance of Bacteroidetes decreased and that of Firmicutes increased,
so that by 15 weeks of age the ratio of the phyla had decreased to ;1
(Fig. 3A). A similar, but slower, change in the composition of gut flora
occurred in the Fmo52/2 mice, with the Bacteroidetes-to-Firmicutes
ratio decreasing to ;3 at 15 weeks and ;1.7 at 30 weeks of age (Fig.
3A). The relative abundance of Actinobacteria, Proteobacteria, and
Deferribacteres was similar in WT and Fmo52/2 mice and did not
change with age (Fig. 3A).
Although the ratio of Bacteroidetes to Firmicutes phyla was the same
in 7-week-old WT and Fmo52/2 mice, the abundance of several
bacterial families differed (Fig. 3B). For instance, Porphyromonadaceae
were more prevalent inWTmice, and Prevotellaceae and Lachnospiraceae
were more prevalent in Fmo52/2 animals. By 30 weeks of age, the
Erysipelotrichaceae family, which was not detected in 7-week-old
mice, was twice as abundant in WT as in Fmo52/2 animals. It is this
family that contributed most to the difference in the ratio of Bacteroidetes
to Firmicutes between 30-week-old WT and Fmo52/2 mice (Fig. 3B).
Six weeks of being fed a high-fat diet had little effect on the relative
abundance of Bacteroidetes and Firmicutes in WT mice, decreasing the
ratio of the phyla from 1.0 to 0.9, but had a marked effect in Fmo52/2
mice, decreasing the ratio from ;1.7 to ;0.4 (Fig. 3A). A lower ratio
of Bacteroidetes to Firmicutes has been associated with an obesogenic
state (Ley et al., 2005; Turnbaugh et al., 2009).
The relative abundance of several bacterial families changed in
response to a high-fat diet (Fig. 3B). In the Bacteroidetes phylum,
Rikenallaceae, reported to increase in response to high-fat feeding
(Daniel et al., 2014), increased inWT but not in Fmo52/2mice, whereas
Porphyromonadaceae decreased, but to a much greater extent (from 33%
to 4%) in Fmo52/2 mice than in WT mice. Within the Firmicutes
phylum, the relative abundance of Lachnospiraceae increased in
Fmo52/2 but not in WT mice. The most striking change was the almost
3-fold increase in Erysipelotrichaceae in Fmo52/2 mice. While being
fed a high-fat diet, this family was the most abundant, comprising about
a third of the total gut microbiota in both WT and Fmo52/2 mice.
Erysipelotrichaceae have been reported to increase with diet-induced
obesity (Kaakoush, 2015). The marked increase in the abundance of this
family in Fmo52/2 mice fed a high-fat diet was not, however,
accompanied by an increase in weight (Fig. 2A). The results indicate
that in the Fmo52/2 mice the composition of gut microbiota changes in
response to diet independently of an obese phenotype and that the
phenotype of Fmo52/2 mice is not influenced by diet or gut flora.
Fig. 2. Fmo52/2 mice are resistant to weight gain and changes
in glucose homeostasis in response to a high-fat diet. (A) Body
weight of WT and Fmo52/2 (KO) mice fed a high-fat diet (WT,
n = 7; KO, n = 6). (B) Plasma insulin concentrations of WT and
KO mice fed standard chow (SC) (n = 3) or fed a high-fat diet
(HFD) for 6 weeks (WT, n = 3; KO, n = 4). (C) GTT of WT and
KO mice fed an SC diet (n = 5) or an HFD for 6 weeks (n = 4).
Insert shows the AUC. (D) Western blot analysis of fecal
proteins from WT mice fed an SC diet or an HFD for 6 weeks.
Each lane represents proteins from a different mouse. M,
molecular mass standards. The blot was incubated with an
antibody against FMO5 and was developed as described in
Materials and Methods. Protein loading was assessed as
described in Materials and Methods. (E) Western blot analysis
of liver proteins from WT mice fed an SC diet or an HFD for
6 weeks. Each lane represents proteins from a different mouse.
The blot was incubated with an antibody against FMO5 or actin
as the internal loading control. The blot was developed as
described in Materials and Methods. Data in (A), (B), and (C)
are expressed as the mean 6 SEM. *P , 0.05, **P , 0.01,
***P , 0.001.
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Treatment with antibiotics for 2weeks had amarked effect onWTmice,
reducing the plasma concentration of glucose (Fig. 3C) and of insulin (Fig.
3D), but had no significant effect on Fmo52/2 mice (Fig. 3, C and D).
Antibiotic treatment also significantly improved the glucose tolerance of
WT mice (Fig. 3E). In the case of Fmo52/2mice, although at initial time
points in the GTT glucose concentrations were lower in antibiotic-treated
mice, the AUC was not significantly different (Fig. 3E), indicating that
antibiotic treatment did not significantly affect the glucose tolerance of the
Fmo52/2mice. Plasma glucose, plasma insulin, and glucose tolerances of
antibiotic-treated WT mice were similar to those of non–antibiotic-treated
Fmo52/2 mice (Fig. 3). Therefore, these metabolic parameters were
profoundly influenced by gut flora inWTmice, but not in Fmo52/2mice,
indicating that the phenotype of Fmo52/2 mice is independent of the gut
microbiota and is determined solely by host genotype.
FMO5 Is Expressed throughout the Murine Digestive Tract. To
determine whether FMO5 is expressed in the gut, sections of the
digestive tract of WT mice were analyzed by immunohistochemistry
(Fig. 4). Sections from the gut of Fmo52/2mice were used as a negative
control. The results revealed that FMO5 was present in the stomach,
duodenum, jejunum, ileum (Fig. 4A), and colon (Fig. 4B). In each of
these tissues, FMO5 was localized to the columnar epithelium of the
mucosa, at the luminal surface. In the stomach, a signal associated with
the lamina propria, at the base of the mucosa, was also observed in
sections from Fmo52/2 mice, indicating that it was due to nonspecific
binding of antibody. Analysis of sections of small intestine (Fig. 4A) and
colon (Fig. 4B) of Fmo52/2 mice resulted in no signal, indicating that
signals obtained from WT mice were specific for FMO5. Analysis of
intestinal “Swiss rolls” confirmed that FMO5 was expressed throughout
the length of both the small intestine and colon in WT mice (data not
shown).
In both the small intestine (Fig. 4A) and large intestine (Fig. 4B),
FMO5 was present throughout the columnar epithelium, including
within goblet cells, which are distinguished from other epithelial cells by
the presence of a visible secretory granule. FMO5 was not present in the
secretory granule itself but was concentrated in the cytoplasm at the
periphery of granules (Fig. 4, A and B). In the colon, the abundance of
FMO5 increased from the base to the luminal opening of crypts (Fig.
4B), in parallel with the maturation of secretory granules.
The staining of transverse sections of stomach, small intestine and
colon with hematoxylin and eosin showed no difference between WT
and Fmo52/2mice in the mucosal thickness or structure of these tissues
(data not shown). Thus, although FMO5 was expressed throughout the
mucosal epithelium of the murine gastrointestinal tract, in Fmo52/2
mice its absence did not affect the gross morphology of the gut.
Fmo52/2 Mice Have Fewer Colonic Goblet Cells. Although there
was no difference in colonic crypt length between WT mice (151.76
3.6mm; n = 57) and Fmo52/2mice (162.16 5.0mm; n = 54), the number
of goblet cells per crypt was significantly lower in Fmo52/2 mice
(15.4 6 0.7; n = 54) than in WT mice (18.5 6 0.8; n = 57; P , 0.01)
(Fig. 4B). Because Fmo52/2mice have fewer goblet cells, we examined
whether this difference influenced the expression of RELMb, a
hormonally active protein present in goblet cell secretory granules,
whose expression is confined to the colon (He et al., 2003). InWTmice,
RELMb was localized to the crypts of the colonic mucosa, where it was
concentrated in the secretory granules of goblet cells (Fig. 4C). As was
the case for FMO5 (Fig. 4B), a gradient of expression of RELMb,
increasing from the base of the crypt to the luminal opening, was
observed, which is in agreement with the findings of a previous report
(He et al., 2003). A similar pattern of RELMb expression was observed
in the colon of Fmo52/2mice (Fig. 4C), indicating that the disruption of
the Fmo5 gene had no effect on the localization of RELMb.
Analysis of proteins extracted from the luminal contents of the colon
(Fig. 4C) identified an ;17 kDa dimeric form of RELMb (He et al.,
2003) in both WT and Fmo52/2 mice. However, in WT mice an
additional band, migrating at;8 kDa, corresponding to the monomeric
form of RELMb (He et al., 2003), was detected. Our results indicate that
although Fmo52/2 mice have fewer colonic goblet cells, disruption of
the Fmo5 gene does not affect the expression of RELMb but may affect
the production of the monomeric form of the protein in the colon. The
expression of RELMb was markedly reduced by antibiotic treatment
(data not shown), as previously reported (Hildebrandt et al., 2009).
Fmo52/2Mice Have Lower Amounts of Inflammatory Markers.
In view of the potential effect of Fmo5 on the production of the
monomeric form of RELMb, we measured markers of inflammation
because, in addition to acting as a mucosecretagogue, RELMb is also
regarded as an inflammatory mediator (Hogan et al., 2006;McVay et al.,
2006; Krimi et al., 2008). The plasma concentration of the inflammatory
cytokine TNFa was ;70% lower in Fmo52/2 mice than in WT mice
(Fig. 5A). Antibiotic treatment decreased the plasma concentration of
Fig. 3. The phenotype of Fmo52/2 mice is independent of gut microbiota. Effect of
age and diet on gut microbial phyla (A) and gut microbial families (B) of WT and
Fmo52/2 (KO) mice. SC, mice were fed an SC diet; HFD, mice were fed an SC diet
then a high-fat diet for 6 weeks. (C) Effect of antibiotic (AB) treatment on plasma
concentrations of glucose of 30-week-old mice fed an SC diet (WT, n = 18; WT + AB,
n = 4; KO, n = 17; KO + AB, n = 6). (D) Effect of AB treatment on plasma insulin
concentration of 30-week-old mice fed an SC diet (n = 3 for each group). (E) Effect of
antibiotic treatment on glucose tolerance of 30-week-old mice fed an SC diet. +AB,
antibiotic treated (WT, n = 3; KO, n = 5); 2AB, untreated (n = 5). Insert shows
the AUC. The GTT was performed as described in Materials and Methods. Data in
(C), (D), and (E) are expressed as the mean6 SEM. *P , 0.05, **P , 0.01, ***P ,
0.001, ****P , 0.0001.
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TNFa inWTmice to a level similar to that in untreated Fmo52/2mice but
had no effect on plasma TNFa levels in Fmo52/2mice (Fig. 5A). As was
the case with plasma TNFa, the amount of C3, a visceral adipose
inflammatorymarker (Hertle et al., 2014), was lower in epididymal adipose
tissue of Fmo52/2 mice than in that of WT mice (Fig. 5B). The plasma
concentration of lipopolysaccharide in Fmo52/2 mice (3.34 6 0.23
enzyme units/ml; n = 3) was the same as that in WT mice (3.11 6 0.06
enzyme units/ml; n = 3), indicating that the disruption of the Fmo5 gene
resulted in no change in intestinal barrier integrity.
Discussion
As WT C57BL/6J mice aged, they exhibited increased plasma
concentrations of glucose and insulin and reduced glucose tolerance
and insulin sensitivity. In contrast, mice in which the Fmo5 gene had
been disrupted, Fmo52/2 mice, were resistant to these changes in
glucose homeostasis and maintained the higher glucose tolerance and
insulin sensitivity that is characteristic of young animals. In response to a
high-fat diet, WTmice increased weight, became hyperinsulinemic, and
displayed markedly reduced glucose tolerance, which are indicative of
increased whole-body insulin resistance. Again, Fmo52/2 mice were
resistant to these changes, indicating that their metabolic phenotype is
independent of diet. Our results demonstrate that disruption of the Fmo5
gene protects mice against diet-induced obesity and the potentially
deleterious effects on glucose homeostasis of both age and the
consumption of high levels of fat and indicate that FMO5 plays a role
in the regulation of body weight and of glucose disposal and insulin
sensitivity.
Other mouse knockout lines are resistant to high-fat diet–induced
weight gain, but in most cases, in contrast to Fmo5, the gene disrupted
encodes a protein with a known role in fat metabolism or its regulation,
for example, protein-tyrosine phosphatase 1B (Klaman et al., 2000),
acetyl-CoA carboxylase 2 (Abu-Elheiga et al., 2012), and Cidea (Zhou
et al., 2003). However, one example in which the product of the
disrupted gene is not involved in fat metabolism or its regulation is that
of RELMb (Hildebrandt et al., 2009).
Although the composition of the gut microbiota of Fmo52/2 mice
changed with age and, in particular, in response to a high-fat diet to a
composition associated with an obesogenic state, these changes had no
Fig. 4. Expression of FMO5 and RELMb in mouse intestine. (A)
Immunohistochemical analysis of sections of stomach and small
intestine of 30-week-old mice. Sections were incubated with an
antibody against FMO5. Top panels, WT mice; bottom panels,
Fmo52/2 (KO) mice. Scale bar, 100 mm. (B) Immunohistochem-
ical analysis of sections of colons from 30-week-old mice. (Top
panels) Sections incubated with antibodies against FMO5.
(Bottom panels) Alcian blue staining of sections of colons from
30-week-old mice. Left-hand panels, WT mice; right-hand panels,
KO mice. Scale bar, 100 mm. (C) Immunohistochemical analysis
of sections of colons of 30-week-old mice. (Top panels) Sections
incubated with antibodies against RELMb. (Bottom panel)
Western blot analysis of colonic content proteins from four WT
and three KO mice. d, dimer; m, monomer; MW, molecular weight
standards. Protein loading was assessed, and the blot was developed
as described in Materials and Methods.
Fig. 5. Fmo52/2 mice have lower amounts of inflammatory markers. (A) Plasma
concentration of TNFa of 30-week-old WT and Fmo52/2 (KO) mice, either
untreated (WT, n = 5; KO, n = 4) or treated with antibiotics (WT, AB; KO, AB) (n = 3).
Data are expressed as the mean6 SEM. *P, 0.05. (B) Western blot analysis of proteins
of WAT of 10-week-old WT and KO mice. The blot was incubated with antibodies
against C3 or enolase, as a loading control. The blot was developed as described in
Materials and Methods.
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effect on the metabolic phenotype of the mice. Disruption of a single
gene, Fmo5, had a similar effect on plasma glucose, plasma insulin, and
glucose tolerance as did antibiotic-mediated removal of gut microbiota
fromWTmice. Indeed, Fmo52/2mice display metabolic characteristics
associated with mice raised in the absence of microorganisms, that is,
germ free, which, in comparison with conventionally rearedmice, weigh
less, store less fat, have lower plasma glucose and insulin concentrations,
and greater insulin sensitivity and glucose tolerance (Backhed et al.,
2007; Rabot et al., 2010). The similarities with germ-free mice suggest
that in Fmo52/2mice gut flora are “invisible” to the host and that FMO5
has a role in sensing or responding to gut bacteria.
Consistent with the proposed involvement of FMO5 in mediating the
host response to gut flora is our finding that the protein is expressed in
the epithelial lining of the gastrointestinal tract. The concentration of
FMO5 at the periphery of secretory granules within goblet cells of the
colon and the increase in the abundance of the protein as the cells
matured suggests a possible role for FMO5 in events associated with the
release or processing of granular components. One such component is
RELMb. Fmo52 /2 mice share some characteristics of a RELMb
knockout mouse (Hildebrandt et al., 2009): both are protected from diet-
induced obesity, and that protection is independent of diet-induced
changes in intestinal microbiota. In addition, the expression of RELMb,
which is confined to the colon (He et al., 2003), is induced in response to
a high-fat diet (Hildebrandt et al., 2009), as was the case for intestinal
FMO5 (Fig. 2D).
Our results indicate that the absence of FMO5 does not affect the
expression of RELMb but may affect production in the colon of the
monomeric form of the hormone. Studies of resistin, which is closely
related to RELMb, indicate that the monomer is the active form of the
hormone (Patel et al., 2004). If this is the case for RELMb, our results
indicate that FMO5 may facilitate production of the active monomeric
form of the hormone in the colon. Given the phenotypic similarities
between Fmo52/2 and RELMb2/2 mice, it is possible that these result,
in part, from altered production of the RELMb monomer in the Fmo52/2
mice.
Reduction in the plasma concentration of the inflammatory cytokine
TNFa as a consequence of disruption of the Fmo5 gene indicates that
FMO5 has a deleterious effect on systemic inflammatory tone. RELMb
has been identified as a promoter of TNFa synthesis and release from
macrophages (McVay et al., 2006). Consequently, the effect of FMO5
on inflammatory tonemight be mediated by its influence on the production
of monomeric RELMb.
In addition to its effects on inflammation, TNFa has detrimental
effects on insulin sensitivity (Kwon and Pessin, 2013), and a TNFa
knockout mouse is protected against obesity-induced glucose intoler-
ance and hyperinsulinemia (Uysal et al., 1997). Thus, our data suggest
that the enhanced whole-body insulin sensitivity of Fmo52/2 mice
results, in part, from the reduced expression of TNFa. The lower amount
of C3 in epididymalWAT of Fmo52/2mice is consistent with the lower
plasma concentration in these animals of TNFa, which plays a role in
regulating the expression of C3 (Cianflone et al., 2003). C3 is associated
with the development of inflammation-linked metabolic disorders and
reduces insulin function (Engström et al., 2005; Samaras et al., 2010;
Hertle et al., 2014). Our findings suggest that reduced expression of C3
in WAT, a consequence of reduced circulating levels of TNFa, would
contribute to the enhanced whole-body insulin sensitivity of Fmo52/2
mice. The proposed indirect effect on WAT of the disruption of the
Fmo5 gene is consistent with the lack of FMO5 expression in this tissue.
Consistent with its role as a regulator of endogenous metabolic
processes, FMO5 displays little genetic variation: within the coding
region only two nonsynonymous SNPs have been identified, both of
which are rare and occur only in individuals of recent African descent
(Furnes et al., 2003; Phillips et al., 2007). FMO1, identified as a
regulator of energy homeostasis (Veeravalli et al., 2014), also displays
little genetic variation (Furnes et al., 2003; Phillips et al., 2007). This is
in marked contrast to FMO2 and FMO3, which are highly polymorphic
(Phillips et al., 2007).
An SNP (rs7541245) within an intron of the FMO5 gene has been
reported to be marginally significantly associated with a decrease in
glycemic response to metformin (Breitenstein et al., 2015). However, it
is not known whether metformin can be metabolized by FMO5 and the
effect of the SNP on expression or activity of FMO5 has not been
established. There is an increasing appreciation of the role of the gut
microbiome in metformin response (McCreight et al., 2016). Thus, if
FMO5 does affectmetformin response, our data suggest that it may do so
via modulation of a host-gut microbiome interaction.
Our results have potential implications for humans. The effect that
FMO5 has on the composition of the gut microbiome suggests that
interindividual differences in the expression of intestinal FMO5 in
humans would alter the gut microbiota and, thus, have potential effects
on the efficacy of orally administered drugs that are metabolized by gut
bacteria.
In addition, our results indicate that interindividual variation in the
expression of FMO5 (Overby et al., 1997) may contribute to differences
in weight gain and insulin sensitivity and that the induction of FMO5 by
some therapeutic agents (Miller et al., 1997; Rae et al., 2001; Krusekopf
and Roots, 2005) may adversely affect the metabolic health of patients.
Thus, FMO5 is identified as a potential novel therapeutic target for
obesity and insulin resistance. Although the lack of FMO5 apparently
promotes a “healthy”metabolic profile, its presence may have conferred
an evolutionary advantage, particularly when food supplies were limited,
by contributing to the ability of mammals, including humans, to deposit
fat and increase weight.
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